trending Market Intelligence /marketintelligence/en/news-insights/trending/foWtvmZ_SUzZujAbizjr3w2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Report: Shanghai Pharma, Fosun Pharma vie for stake in Arbor Pharmaceuticals

Street Talk Episode 68 - As many investors zig away from bank stocks, 2 vets in the space zag toward them

Street Talk Episode 66 - Community banks tap the debt markets while the getting is good

Street Talk Episode 67 - Veteran investor tabs Mick Mulvaney to help with latest financial stock-focused fund

Street Talk Episode 65 - Deferral practices trap US bank portfolios in purgatory

Report: Shanghai Pharma, Fosun Pharma vie for stake in Arbor Pharmaceuticals

Shanghai Pharmaceuticals Holding Co. Ltd. and Shanghai Fosun Pharmaceutical (Group) Co. Ltd. are bidding for a stake in U.S. drugmaker Arbor Pharmaceuticals LLC, Bloomberg News reported, citing people familiar with the matter.

According to the sources, the buyer would acquire 20% to 30% of the KKR & Co. LP-backed specialty pharmaceutical company.

Arbor may use the capital raised from the deal — valued between $600 million and $700 million — to grow its business ahead of a potential IPO, Bloomberg said.

Back in March, the Chinese pharmaceutical giant was linked to a potential bidding war for Stada Arzneimittel AG, offering up to $4 billion for the German drugmaker.

Earlier in August, Fosun's $1.3 billion bid to buy Gland Pharma Ltd. was blocked by India's Cabinet Committee on Economic Affairs.

Shanghai Pharma is separately mulling over acquiring Cardinal Health Inc.'s Chinese business since it was put on the block in July.

Atlanta-based Arbor Pharmaceuticals LLC specializes in prescription medication in the cardiovascular, hospital and pediatric markets. Its developmental product pipeline also includes medicines in urology, oncology, psychiatry and dermatology.